share_log

凯赛生物(688065.SH):开发的生物基聚酰胺连续纤维复合材料已在新能源、现代建筑、交运物流等领域开始样品试制和验证

Cathay Biotech Inc. (688065.SH): The developed bio-based polyimide continuous fiber composite materials have begun sample trial production and verification in the fields of new energy, modern architecture, transportation logistics, etc.

Gelonghui Finance ·  Nov 21, 2024 15:43

On November 21, Gelonghui reported that cathay biotech inc. (688065.SH) stated on the investor interaction platform that currently, the bio-based polyamide continuous fiber composite materials developed by the company have begun sample production and validation in the fields of new energy fund, modern construction, and logistics. Based on the cost-performance advantages and market potential of these bio-based new materials, the company has conducted business connections with multiple subsidiaries and joint ventures of China Merchants Group, and several pilot projects are underway.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment